← Back to Search

Remote Patient Monitoring and Health Coaching for High Blood Pressure

Stanford University, Redwood City, CA
Omada Hypertension ProgramN/ARecruitingLed by Steven Lin, MDResearch Sponsored by Stanford University

Study Summary

This trial is testing whether a digital program that includes personalized health coaching and remote patient monitoring can improve blood pressure control compared to usual care.

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have been diagnosed with high blood pressure.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean change from baseline in systolic blood pressure at 1-year
Secondary outcome measures
Mean change from baseline in A1c at 1-year
Mean change from baseline in weight at 1-year

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Receives access to Omada Health programExperimental Treatment1 Intervention
In addition to usual care, participants will gain access to the Omada Program, an online program that offers lifestyle self-management support for hypertension. Participants will be assigned a health coach and a hypertension specialist via Omada's secure app. Participants will receive hypertension education and resources and communicate with their care team through asynchronous, in-app messaging features. Participants will receive digital tools that connect with the Omada app to help track their food intake, physical activity, and blood pressure (BP). Participants who also have diabetes will receive a digital blood glucose meter and/or a continuous glucose monitor as well. The care team will support patients with lifestyle self-management support, adherence to their current medication regimen, improved BP control, and use of monitors for self-management of their BP and/or blood glucose values.
Group II: Does not receive access to Omada Health programActive Control1 Intervention
Participants manage hypertension with usual care alone.

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,324 Previous Clinical Trials
17,287,398 Total Patients Enrolled
Omada Health, Inc.Industry Sponsor
4 Previous Clinical Trials
1,052 Total Patients Enrolled
Steven Lin, MDPrincipal InvestigatorStanford University
1 Previous Clinical Trials
39 Total Patients Enrolled

Media Library

Omada Hypertension Program Clinical Trial Eligibility Overview. Trial Name: NCT05394766 — N/A
High Blood Pressure Research Study Groups: Receives access to Omada Health program, Does not receive access to Omada Health program
High Blood Pressure Clinical Trial 2023: Omada Hypertension Program Highlights & Side Effects. Trial Name: NCT05394766 — N/A
Omada Hypertension Program 2023 Treatment Timeline for Medical Study. Trial Name: NCT05394766 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the maximum number of people who can enroll in this trial?

"The answer is affirmative, the trial in question is still recruiting individuals according to the information available on clinicaltrials.gov. This specific study was posted on 7/29/2022 and updated for the last time on 8/2/2022. They are looking for 550 participants total, with recruitment happening at a single site."

Answered by AI

Are we currently accepting participants for this trial?

"That is correct. The listing on clinicaltrials.gov for this study shows that it is actively recruiting patients. This trial was posted on 29 July 2022 and updated on 2 August 2022. They are looking to enrol 550 people at a single site."

Answered by AI
~167 spots leftby Jul 2024